MIVT: MIV THERAPEUTICS´FIRST IN-MAN STUDY DATA ‘VERY ENCOURAGING’ ACCORIDNG TO SISM RESEARCH MORNING NOTE
NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst with Investrend affiliate SISM Research and a four star analyst according to StarMine, has reiterated his “Speculative Buy/4” Rating and 12-18 month target price of $2.50 for MIV Therapeutics, Inc. (OTCBB: MIVT - News) in a Morning Note. Full Report-HTM Analyst Report - PDF

MIVT: MIV PRELIMINARY NINE-MONTH HUMAN DATA AFFIRMS EXCELLENT SAFETY AND EFFICACY OF VESTASYNC™ POLYMER-FREE-DRUG-ELUTING STENT
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics, Inc. (OTCBB:MIVT - News) (Frankfurt:MIV - News), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that nine month results from the first-in-man (FIM) MIVT Pilot Trial of its VESTAsync™ drug-eluting stent suggest that the stent has the potential for superior safety and equivalent efficacy when compared to currently available drug-eluting stents. Jose Costa, M.D. of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil discussed the preliminary data in a moderated poster presentation yesterday at the 57th Annual Scientific Sessions of the American College of Cardiology in Chicago. The presentation titled, “Preliminary Results of the Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent for the Treatment of Single de novo Coronary Lesions: A First-in-Human Analysis of a Third-Generation Drug-Eluting Stent System” concluded that the VESTAsyncTM polymer-free nanoscale microporous hydroxyapatite stent demonstrates excellent efficacy and safety. Full Report-HTM

MIVT: MIV THERAPEUTICS RECEIVES 2008 FROST & SULLIVAN NORTH AMERICA AWARD FOR TECHNOLOGY INNOVATION
ATLANTA, GA--(MARKET WIRE)--Feb 25, 2008 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that the company received the Frost & Sullivan 2008 North America Technology Innovation Award in the field of interventional cardiology. Frost & Sullivan will present the award to Dr. Mark Landy, president and chief executive officer of MIV, at the 2008 Excellence in Medical Technologies & Life Sciences Awards Banquet on Wednesday, March 12, 2008 at the Hyatt Fisherman's Wharf in San Francisco. Full Report-HTM

MIVT: MIV THERAPEUTICS APPOINTS MARK LANDY TO ADDITIONAL POST OF CHIEF EXECUTIVE OFFICER
ATLANTA, GA--(MARKET WIRE)--Jan 7, 2008 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that Dr. Mark Landy, president, will assume the additional position of chief executive officer of the company effective today. He assumes this position from Alan Lindsay, who will remain chairman of the board of MIV Therapeutics. Full Report-HTM

MIVT: MIVT THERAPEUTICS RECEIVES INDIA REGULATORY APPROVAL FOR TWO BARE METAL STENTS
ATLANTA, GA--(MARKET WIRE)--Nov 12, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that the Drugs Controller General of India (DCGI), the governmental agency with regulatory authority over medical products, has approved two of the Company's bare metal stents for manufacture and sale in India. Full Report-HTM

MIVT: MIVT THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM FIRST HUMAN STUDY WITH ITS VESTASYNC STENT
ATLANTA, GA--(MARKET WIRE)--Oct 16, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that results of the first-in-man safety study with the Company's drug-eluting stent will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2007 conference, to be held October 20-25 at the Washington Convention Center in Washington, D.C. Full Report-HTM

MIVT: RESULTS OF FIRST-IN-MAN STUDY WITH MIVT LOW DOSE POLYMER-FREE DRUG-ELUTING STENT TO BE PRESENTED AT TCT CONFERENCE
ATLANTA, GA--(MARKET WIRE)--Oct 16, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that results of the first-in-man safety study with the Company's drug-eluting stent will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2007 conference, to be held October 20-25 at the Washington Convention Center in Washington, D.C. Full Report-HTM

MIVT: MIVT THERAPEUTICS ANNOUNCES RESEARCH COLLOBARATION WITH SMITH & NEPHEW
ATLANTA, GA--(MARKET WIRE)--Sep 27, 2007 -- MIV Therapeutics (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced a research collaboration with contributions in kind from both Smith & Nephew and MIV Therapeutics to develop new coatings and drug delivery systems for orthopedic devices.Full Report-HTM

MIVT: MIV THERAPEUTICS APPOINTS ERNST & YOUNG AS NEW AUDITOR
Appointment Addresses Company's Need to Increase International Capabilities After Recent Acquisitions. Full Report-HTM

MIVT: MIV THERAPEUTICS NAMES METHODIST HOSPITAL RESEARCH CARDIOLOGIST DR. GREG KALUZA TO SCIENTIFIC ADVISORY BOARD
World Renowned Specialist Contributes Extensive Clinical Expertise as Company Moves to Next Phase of Development and Commercialization. Full Report-HTM

MIVT: MIV THERAPEUTICS ANNOUNCES START OF CLINICAL TRIAL MARKING FIRST EVER HUMAN IMPLANTATION OF A HYDROXYAPATITE COATED STENT
Trial to Study Safety and Efficacy of One of the Company's Proprietary Polymer-Free Drug-Eluting Stent Technologies. Full Report-HTM

MIVT: MIV THERAPEUTICS APPOINTS INTERNATIONALLY RENOWNED CARDIOLOGIST AND CHIEF EXECUTIVE OFFICER OF KAILASH HEART INSTITUTE AS CLINICAL ADVISOR
World Renowned Specialist Contributes Extensive Clinical Trial Expertise. Full Report-HTM

MIVT: MIV THERAPEUTICS ANNOUNCES RENOWNED RESEARCHER TO DETAIL MILESTONE PRE-CLINICAL RESULTS AT PROMINENT INTERNATIONL CONFERENCE EUROPCR 2007
Third Party Presentation to Feature Study Showing Proprietary Technology Matches or Outperforms Current Stent Technology in Key Categories. Full Report-HTM

MIVT: MIV THERAPEUTICS ESTABLISHES PRESENCE IN EUROPE AND ENGAGES INFLUENTIAL BUSINESS DEVELOPMENT FIRM QUILT SOLUTIONS
MIVT to Open Office in Basel, Switzerland, to Focus on Sales and Marketing of Recently Acquired CE-Marked Products into Lucrative European Markets. Full Report-HTM

MIVT: MIV THERAPEUTICS TARGETS MULTIBLILION MEDICAL DEVICE MARKET IN RESEARCH NOTE BY INVESTREND AFFILIATE SISM RESEARCH
This month, MIVT generated its first revenue in Company history. These sales clearly vali-date the mission of the Company to become a leader in interventional cardiology. MIVT is now targeting an eight billion dollar cardiovascular stent market that includes Europe, Asia, and India. In addition, MIVT expects to bring its polymer-free hydroxyapatite coating plat-form to the market place soon. Trial programs in 2006 indicate that MIVT’s polymer-free technology is at least as good, and in some cases better than, Johnson & Johnson's Cypher stent, currently the world’s best-selling drug-eluting stent. First human implantation is planned within the next few months. Stroke is the third leading cause of death and one of the most feared complications of surgery. Scientific data show that the extent of stroke following heart surgery is alarming. MIVT’s novel proprietary device targets a $58 billion industry to prevent embolic strokes after cardiac surgery. The Company has entered a rapid phase of testing and regulation for its device. Market entry for the product is expected in Europe within 12 months and in the US within 24 months. Today, MIVT is an undiscovered company with a huge opportunity in a very large market. We maintain our view that MIVT is still significantly undervalued and consequently reaffirm our 12-month target price of $2.50. Full Analyst Report - PDF

MIVT: MIV THERAPEUTICS ANNOUNCES FIRST EVER REVENUES FROM CARDIOVASULAR PRODUCTS APPROVED FOR EUROPEAN AND OTHER MARKETS
Sales of Recently Acquired CE-Marked Devices Initiate Commercialization of Broad and Expanding Product Portfolio. Full Report-HTM

MIVT: MIV THERAPEUTICS HIGHLIGHTS HIGH-GROWTH BUSINESS MODEL, NEXT GENERATION STENT TECHNOLOGIES AND TARGETED $8 BILLION MARKET IN UPDATED INVESTOR FACT SHEET
Company Details Global Reach with Recent Acquisition of Biosync Scientific to Expand Product Offerings and Manufacturing Capabilities. Full Report-HTM

MIVT: MIV THERAPEUTICS ANNOUNCES ADDITION OF EIGHT NEW APPROVED PRODUCTS FOLLOWING RECENT ACQUISTION OF INDIA-BASED STENT MANUFACTURER
CE-Marked Products Already Approved for Commercialization in Europe, India, Asia and Other Highly Lucrative Markets. Full Report-HTM

MIVT: MIV THERAPEUTICS ANNOUNCES ADDITION OF VETERAN MANAGEMENT TEAM FOLLOWING RECENT ACQUISTION OF INDIA-BASED BIOSYNC
Renowned Biosync Team to Accelerate Commercialization of Next Generation Stents Targeting $8 Billion Market. Full Report-HTM

MIVT: MIV THERAPEUTICS ANNOUNCES PIVOTAL TEST RESULTS FURTHER VALIDATING COMPANY STENT COATINGS MEET CRITICAL FDA FATIGUE GUIDELINES
Bench Test Merged Biosync Stent Platform with Company's Biocompatible Coating, Validating Milestone Acquisition of India-Based Subsidiary. Full Report-HTM

MIVT: MIV THERAPEUTICS COMPLETES ACQUISTION OF BIOSYNC TO EXPAND OPERATIONS AND ACCELERATE COMMERCIALIZATION IN FAST-GROWING MARKET
Publications in New England Journal of Medicine Further Validates Need for Company's Novel Technology in Estimated $58 Billion Industry.Full Report-HTM

MIVT: MIV THERAPEUTICS COMPLETES ACQUISTION OF BIOSYNC TO EXPAND OPERATIONS AND ACCELERATE COMMERCIALIZATION IN FAST-GROWING MARKET
Acquisition to Bring Seven Valuable CE Marked Products and Highly Competitive Bare Metal Stent Platform. Full Report-HTM

MIVT: MIV THERAPEUTICS RELEASES CEO LETTER TO SHAREHOLDERS HIGHLIGHTING RECENT STRATEGIC ACHIEVEMENTS AND PROGRESS
CEO Cites Recent Milestone Agreement to Acquire China-Based Vascore Medical and India-Based Biosync Scientific to Accelerate Commercialization of Next Generation Stent Technology. Full Report-HTM

MIVT: MIV THERAPEUTICS EXECUTES PRIVATE FINANCINGS FOR $4 MILLION TO SUPPORT ACQUISTIONS, DEVELOPMENT AND DISTRIBUTION OF NEXT GENERATION STENTS
Placement Follows Recent Agreements to Acquire Established Indian and Chinese Interventional Cardiology Companies. Full Report-HTM

MIVT: INVESTREND AFFILIATE SISM RESEARCH ‘MORNING NOTE’ REITERATES MIV THERAPEUTICS `BUY/4 RATING’ $2.50 TARGET VALUATION, CITING PLANS TO INTRODUCE NEW PRODUCTS IN EUROPE KEY GLOBAL MARKETS NEXT QUARTER
MIV Therapeutics (OTCBB: MIVT) announced Biosync’s seven new CE Mark-certified cardiovascular stents and related products to be sold in India, then Europe, Asia and Latin America. (OTCBB: MIVT) announced Biosync’s seven new CE Mark-certified cardiovascular stents and related products to be sold in India, then Europe, Asia and Latin America. Full Report-HTM ANALYST-REPORT-PDF ANALYST-REPORT-PDF IN GERMAN

MIVT: MIV THERAPEUTICS ANNOUNCES MARKET LAUNCH OF THE GENX CRCO STENT AND SEVEN ASSOCIATED INTERVENTION CARDIOLOGY PRODUCTS BY BIOSYNC SCIENTIFIC
Launch is a Key Milestone in the Company's Mission to Deliver a Broad Range of Products to the Interventional Cardiology Community. Full Report-HTM

MIVT: MIV THERAPEUTICS INC GAINS 31.6% ON 13X VOLUME
December 13, 2006 (FinancialWire) MIV Therapeutics Inc (OTCBB: MIVT) gained 31.65% Tuesday on volume of 2,455,106, which was almost 13 times its three-month average 190,280, to end the day at $1.04. Full Report-HTM

MIVT: MIV THERAPEUTICS INC GAINS 33.9% ON 7X VOLUME
December 12, 2006 (FinancialWire) Miv Therapeutics Inc (OTCBB: MIVT) gained 33.9% Monday on volume of 1,232,695, which was seven times its three-month average 173,838, to end the day at $0.79. Full Report-HTM

MIVT:MIV THERAPEUTICS EXECUTES MILESTONE AGREEMENT TO ACQUIRE BIOSYNC SCIENTIFIC, A LEADING INDIAN INTERVENTIONAL CARDIOLOGY COMPANY
Acquisition Provides MIVT with Highly Competitive CE Marked Bare Metal Stent Platform. Full Report-HTM

MIVT: MIV THERAPEUTICS INC GAINS 18% ON 2X VOLUME
December 11, 2006 (FinancialWire) MIV Therapeutics Inc (OTCBB: MIVT) gained 18% Friday on volume of 408,585, which was more than twice its three-month average 168,178, to end the day at $0.59. Full Report-HTM

MIVT: MIV THERAPEUTICS ‘BUY/4’ RATING, $2.50 TARGET VALUATION REITERATED IN RESEARCH NOTE BY INVESTREND AFFILIATE SISM RESEARCH, INDICATING GRATER MARKET POTENTIAL AND CITING RECENT SUPERIOR PERFORMANCE OF STENT COATING TECHNOLOGIES IN RECENT TESTS
MIVT's Biocompatible Polymer-Free Drug-Eluting Stent Coating Technologies Shown in Tests to be Better Than the Industry's Benchmark Cypher Stent, One of the World's Best Selling Drug-Eluting Stents. Full Report-HTM ANALYST REPORT-PDF

MIVT: MIV THERAPEUTICS MAINTAINS ‘BUY/4’ Rating and $2.50 12-MONTH TARGET VALUATION IN RESEARCH NOTE BY INVESTREND AFFILIATE SISM RESEARCH
MIV Therapeutics (OTCBB: MIVT) Recent tests have sown MIV Therapeutics’ (OTCBB: MIVT) biocompatible polymer-free drug-eluting stent coating technologies shown to be Better Than the Industry’s Benchmark Cypher Stent. Full Report-HTM Research Note - PDF

MIVT: MIV THERAPEUTICS INC. GAINS 42.11% ON 10X VOLUME
December 1, 2006 (FinancialWire) MIV Therapeutics Inc (OTCBB: MIVT) gained 42.11% Thursday on volume of 1,501,577, which was more than ten times its three-month average 142,869, to end the day at $0.54. Full Report-HTM

MIVT: MIV THERAPEUTICS ANNOUNCES COMPANY’S BIOCOMPATIBLE STENTS MATCHES OR OUTPERFORMS WORLD’S LEADING DRUG-ELUTING STENT IN KEY CATEGORIES
Excellent Results from Preclinical Study of Biocompatible Polymer-Free Drug Eluting Stent Coating Technologies Paves the Way Towards Human Trials. Full Report-HTM

MIVT: HUMAN TRIALS ARE ONLY A SHORT PERIOD AWAY
MIVT has extended its corporate success into 2006. In preparation for coming clinical trials that will commence in early 2007, the Company successfully completed an exten-sive range of animal studies, confirming the biocompatibility and safety of its crown technologies for the cardiovascular industry: polymer-free coatings for stents. Full Analyst -Report-PDF

MIVT: MIV THERAPEUTICS ANNOUNCES TIMELINE FOR FIRST HUMAN IMPLANTATION OF HAP NANO-FILM COATED STENT
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible drug-eluting stents, announced today that it intends to begin the first human implants of a HAp NanoFilm coated stent early in 2007. Full Report-HTM

MIVT: MIV THERAPEUTICS DETAIL RESEARCH RESULTS SHOWING EXCELLENT PERFORMANCE OF BREAKTHROUGH STENT COATINGS AT TCT CONFERENCE
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), announced that Dr. Greg Kaluza, Scientific Director, Center for Research in Cardiovascular Interventions at The Methodist Hospital Research Institute, Houston, TX, who directed the independent preclinical study of MIVT's stent coatings will present recent results of a long-term animal study of its proprietary stent coating technology at the Annual Transcatheter Cardiovascular Therapeutics (TCT) 2006 conference in Washington, D.C., the field's largest scientific meeting. Full Report-HTM

MIVT: MIV THERAPEUTICS CITED AS LEADING TECHNOLOGY INNOVATOR IN CARDIOVASCULAR DEVICE INDUSTRY REPORT BY FROST & SULLIVAN
ATLANTA--(BUSINESS WIRE)--Sept. 19, 2006--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that the widely respected global consulting firm Frost & Sullivan has cited the Company's innovative stent coating technology as among the most advanced of the emerging class of biocompatible third generation cardiac stents under development. Full Report-HTM

MIVT: MIV THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE VASCORE MEDICAL CO. LTD., LEADING CHINESE MANUFACTURER OF ADVANCED CARDIOVASCULAR STENTS
VANCOUVER, B.C.--(BUSINESS WIRE)--Sept. 13, 2006--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced that it has entered into a formal agreement to acquire, subject to the prior satisfaction of certain conditions, Vascore Medical (Suzhou) Co., Ltd., a China-based manufacturer of advanced cardiovascular stents and other medical devices. Full Report-HTM

MIVT: MIV THERAPEUTICS FILES THREE NEW US PATENTS FOR BREAKTHROUGH STROKE-PREVENTING TECHNOLOGY FROM SAGAX SUBSIDIARY
ATLANTA--(BUSINESS WIRE)--Aug. 18, 2006--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that its subsidiary, SagaX, has filed three new patents with the U.S. Patent Office related to a proprietary implantable filtration device designed to help prevent common stoke complications during and after a range of common invasive heart procedures. Full Report-HTM

MIVT: MIV THERAPEUTICS TO UNVEIL TECHNOLOGIES TARGETING $23 BILLION ORTHOPEDICS DEVICE MARKET
ATLANTA--(BUSINESS WIRE)--Aug. 10, 2006--MIV Therapeutics (OTCBB:MIVT FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, will unveil technology to address multiple revenue opportunities in the $23 billion orthopedic device market at the upcoming World Orthopedic Organization (SICOT) conference in Buenos Aires, later this month. Full Report-HTM

MIVT: MIV THERAPEUTICS’ SUBSIDIARY SAGAX ACCELERATES DEVELOPMENT OF SURGICAL STROKE PREVENTION DEVICE TOWARDS COMMERCIALIZATION
First Generation Device Could be Ready for Clinical Use Within 14 MonthsAdditions to SagaX Team Strengthens Management and Accelerates Development of Novel Stroke Prevention Device. Full Report-HTM

MIVT: MIV THERAPEUTICS’ SUBSIDIARY SAGAX ACCELERATES DEVELOPMENT OF SURGICAL STROKE PREVENTION DEVICE TOWARDS COMMERCIALIZATION
First Generation Device Could be Ready for Clinical Use Within 14 MonthsAdditions to SagaX Team Strengthens Management and Accelerates Development of Novel Stroke Prevention Device. Full Report-HTM

MIVT: MIV THERAPEUTICS’ SUBSIDIARY SAGAX ANNOUNCES APPOINTMENT OF NEW EXECUTIVES AND TECHNOLOGY SPECIALISTS
Additions to SagaX Team Strengthens Management and Accelerates Development of Novel Stroke Prevention Device. Full Report-HTM

MIVT: MIV THERAPEUTICS’ HIRE NOTED PHARMACOLOGY SCIENTIST DR. VLAD BUDZYNSKI TO DIRECT MULTIPLATFORM DRUG DELIVERY PROGRAM
Veteran Researcher and University Professor Brings Expertise in Drug Development and Advanced Biomedical Solutions. Full Report-HTM

MIVT: MIV THERAPEUTICS’ EXECUTES AGREEMENT TO COLLABORATE ON FUTURE DRUG ELUTING STENT TECHNOLOGIES WITH SAHAJANAND
Agreement with Stent Manufacturer to Involve Potential Cross-Licensing and Other Development Initiatives. Full Report-HTM

MIVT: MIV THERAPEUTICS’ SHARE PRICE TARGET PROJECTION INCREASED TO $1.77 IN NEW REPORT UPDATE FROM BEACON EQUITY RESEARCH
Company Officers Outline Recent Strategic Achievements and Product Development Initiatives at Shareholders Meeting. Full Report-HTM

MIVT: MIV THERAPEUTICS’ SHARE PRICE TARGET PROJECTION INCREASED TO $1.77 IN NEW REPORT UPDATE FROM BEACON EQUITY RESEARCH
Raised Share Price Target Reflects Continued Progress to Develop Breakthrough Solutions for Stents and Drug-Delivery Systems. Full Report-HTM Analyst Report

MIVT: MIV THERAPEUTICS 6-MONTH PRICE TARGET OF $2.50 REAFFIRMED IN NEWLY UPDATED SISM RESEARCH REPORT
Biocompatible Stent Coating Developer's Progress Reflected in Robust Target Price Re-Statement and Speculative Buy Rating. Full Report-HTM Summary - Analyst Report

MIVT: MIV THERAPEUTICS HIGHLIGHTS 2005 SCIENTIFIC AND STRATEGIC MILESTONES IN DEVELOPMENT OF NEW GENERATION BIOMEDICAL TECHNOLOGIES
Year-End Report Cites Achievements in Breakthrough Drug Delivery and Other Solutions for Multi-Billion-Dollar Markets. Full Report-HTM

MIVT:MIV THERAPEUTICS SPOTLIGHTS NEWEST CLINICAL RESULTS OF COMPANY’S HAP-BASED STENT COATING ON BIOMEDDISCOVERIES.COM
Chief Medical Officer Describes Positive Outcomes of Pivotal Study of Biocompatibility Coatings in Interview. Full Report-HTM

MIVT:MIV THERAPEUTICS REPORTS HIGHLY FAVORABLE RESULTS IN PRECLINICAL STUDY OF INNOVATIVE STROKE PREVENTION DEVICE
Unique Implantable Anti-Stroke Device Progress on Track for Approval and Potential Commercialization. Full Report-HTM

MIVT:MIVT’S PROPRIETARY STENT COATING TECHNOLOGY COMPLETES MAJOR LONG-TERM ANIMAL STUDY WITH EXCELLENT RESULTS
Six-Month Study Demonstrates Unparalleled Biocompatibility and Safety of MIVT HAp Coatings for Drug-Eluting Stent Applications. Full Report-HTM

MIVT:MIVT DISCUSSES POSITIVES INTERIM RESEARCH RESULTS ON PATH TO COMMERCIALIZE NEW GENERATION STENT COATINGS
Chief Technology Officer Cites Interim Results of Long-Term Animal Studies in Anticipation of Final 6 Month Results and Report in Interview with BiomedDiscoveries.com.Full Report-HTM

MIVT: MIV THERAPEUTICS OFFICIALLY NAMED WINNER OF PRESTIGIOUS AWARD FOR INNOVATION IN ADVANCED BIOMEDICAL TECHNOLOGY
Frost & Sullivan Report Praises MIVT Proprietary Biocompatible Coating Technology for Stents and Other Biomedical Devices - VANCOUVER, British Columbia--(BUSINESS WIRE)--Oct. 21, 2005--MIV Therapeutics, Inc. a developer of next-generation biocompatible stent coatings and drug delivery technologies, has officially been named winner of Frost & Sullivan's prestigious 2005 Award for Technology Innovation in the Field of Advanced Medical Coatings.Full Report-HTM

MIVT: MIV THERAPEUTICS FILES BOTH US AND INTERNATIONAL PATENTS FOR BREAKTHROUGH SMART III NANOPARTICLE DRUG DELIVERY SYSTEM
Cutting-Edge Nanotechnology Particulate System Could Revolutionize Drug Delivery Methods to Treat Major Diseases - VANCOUVER, British Columbia--(BUSINESS WIRE)-- Oct. 7, 2005--MIV Therapeutics, Inc. a developer of next-generation biocompatible stent coatings and drug delivery technologies, today announced the filing of landmark US and international Patent Cooperation Treaty (PCT) patent applications for the newest member of its advanced "Smart" drug delivery systems, designed to meet the individual needs of millions of patients. Full Report-HTM

MIVT: MIV THERAPEUTICS GAINS 11.76% ON 2X AVERAGE VOLUME AFTER RESEACH REPORT
October 3, 2005 (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 11.76% on volume of 1,005,536, almost twice its average volume of 644,168, to close at $1.52 after Ernest C. Schlotter, a senior analyst with Investrend Research affiliate SISM Research, and a four-star analyst according to San Francisco-based StarMine, reiterated his Speculative Buy/4 rating for the company and set a new 6-month price target of $2.50.Full Report-HTM

MIVT: MIV THERAPEUTICS’ SIX-MONTH SHARE PRICE TARGET RAISED 100% TO $2.50 IN NEWLY AVAILABLE REPORT FROM SISM RESEARCH
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 30, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; Frankfurt/FSE:MIV), a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced the availability of a new research report targeting the Company's six-month share price at $2.50, an approximate doubling of the recent share value, with a speculative Buy/4 Rating. The report was issued by SISM Research and Investment Services. Full Report-HTML Summary in PDF

MIVT: SISM RESEARCH KEEPS @ SPECULATIVE BUY; UPS TGT TO $2.5 VS $1.5; ANALYST NOTES
Target Price Action: INCREASE, Target Price: $2.50 (+66.67% from $1.50) Analyst Comments: The firm notes that since their June updated report, the stock has tripled in price but there is still considerable value to be unlocked. MIVT gained investors confidence based on very encouraging results from its latest animal trials which pave the way for human clinical trials scheduled to commence in early 2006. They also point out that MIVTapeutics also won the prestigious Frost & Sullivan 2005 Technology Innovation Award for Advanced Medical Coatings. MIVT's planed acquisition of Sahajanand Medical Technologies Inc. has not yet bee completed, but the firm believes it will be soon. SMT's state-of-the-art production technology and worldwide distribution, combined with MIVT's proprietary coating technology, will provide a powerful synergy that will make MIVT a major industry player in which MIVT become a major commercial provider in the rapidly growing market for both cardiac and other types of implantable medical devices, in the firm's opinion. Full Report - HTML

MIVT: MIV THERAPEUTICS INVEST IN ADDITIONAL EQUIPMENT AND SCIENTIFIC PERSONNEL IN REFLECTION OF R&D EXPANSION
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 28, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; Frankfurt/FSE:MIV), a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced today that it has expanded its comprehensive innovation and development program to improve advanced vascular stents and internal drug-delivery systems.Full Report - HTML

MIVT: MIV THERAPEUTICS GAINS 26.13% ON SLIGHTLY HIGHER VOLUME
September 28, 2005 (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 26.13% on volume of 682,160, slightly higher than its usual 624,059, to close at $1.40. Full Report - HTML

MIVT: MIV THERAPEUTICS’ INTELLECTUAL PROPERTY PRTFOLIO EXPANDS TO 43 PATENTS, PATENT APPLICATONS AND LICENSES ON NOVEL TECHNOLOGIES
Aggressive IP Protection of Coating Technologies Positions Company for Entry into $100 Billion Drug-Delivery Market. Full Report - HTML

MIVT: MIV THERAPEUTICS NAMES ARC RATJAR TO POST OF CHIEF TECHNOLOGY OFFICER AS COMPANY ACCELERATES R&D PROGRAMS
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 23, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced today that it has promoted veteran biomedical industry engineer Arc Rajtar, MSc. Eng., to the position of Chief Technology Officer, in a move that reflects a highly dynamic period and accelerated pace of development at the Company.Full Report - HTML

MIVT: MIV THERAPEUTIC’S BREAKTHROUGH AORTIC EMBOLIC PROTECTION DEVICE HIGHLIGHTED IN NEW INTERVIEW ON BIOMEDDISCOVERIES.COM
LOS ANGELES, Sept. 19, 2005 (PRIMEZONE) - BiomedDiscoveries.com, http://www.biomeddiscoveries.com/bd/, the online source for exclusive investor information in the biotechnology sector, has made available a new Q&A-style interview with leading international cardiac specialist, Dr. Dov Shimon, the Chief Medical Officer and Director of MIV Therapeutics (OTC BB:MIVT.OB - News) (Frankfurt:MIVF.F - News), which develops next-generation biocompatible coatings and drug delivery technologies.Full Report - HTML

MIVT: MIV THERAPEUTICS PASSIVE STENT COATINGS ACCEPTED FOR PRESENTATION AT PRESTIGIOUS WORLD CONFERENCE ON CARDIOVASULAR THERAPY
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 12, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced that interim results of a long-term animal study of its proprietary ultra-thin Hydroxyapatite coating will be featured at this year's 17th annual Transcatheter Cardiovascular Therapeutics (TCT) 2005 conference in Washington, D.C. Full Report - HTML

MIVT: MIV THERAPEUTICS NEWEST TECHNOLOGY BRAKTHROUGH EXPANDS FAMILY OF PROPERITARY “SMART” DRUG DELVIERY SYSTEMS
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 2, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies for the treatment of cardiovascular disease and therapeutic applications on implantable medical devices, announced today a milestone scientific achievement related to the development of a new drug delivery system with "smart" drug-eluting coating technologies. Full Report - HTML

MIVT: MIVT THERAPEUTICS FURTHER EXPANDS IP PORTFOLIO WITH MILESTONE ADDITON OF TWO NEW U.S. PROVISIONAL PATENT APPLICATIONS
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 30, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced today a major milestone in further expanding its intellectual property rights with the filing of two new U.S. patent applications by the University of British Columbia, a technology development partner of MIVT. Full Report - HTML

MIVT: MIVT RECEIVES PRESTIGIOUS FROST & SULLIVAN 2005 AWARD FOR TECHNOLOGY INNOVATION IN FIELD OF MEDICAL COATINGS
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 24, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug delivery technologies for the treatment of cardiovascular disease, has been recognized by Frost & Sullivan with the 2005 Technology Innovation Award, in recognition of the Company's achievements and pioneering work to develop proprietary biocompatible coatings technology to make better, safer vascular stents, medical devices and drug delivery systems.Full Report - HTML

MIVT: MIV THERAPEUTICS CLOSES $4.14 MILLION EQUITY FINANCING
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 22, 2005--MIV Therapeutics, Inc. (OTCBB: MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies for cardiovascular stents and for broad range of implantable medical devices, has recently closed a Reg S and Rule 506 non-brokered private placement financing totaling $4.14 million. Full Report - HTML

MIVT: MIV THERAPEUTICS BRAKTHROUGH TECHNOLOGY PRAISED IN INDEPENDENT RESEARCH SERVICE BY FROST & SULLIVAN
MIV VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 17, 2005--MIV Therapeutics, Inc. (OTCBB: MIVT - News), a developer of next-generation biocompatible and drug-delivery coatings for cardiovascular stents, has been extolled as one of the leading companies in the field of advanced medical coatings in a newly released research service from Frost & Sullivan, a highly respected global independent research and growth consulting firm. Full Report - HTML

MIVT: MIV THERAPEUTICS SUCCESSFULLY COMPLETES ANIMAL FEASIBILITY STUDIES OF STROKE-PREVENTION DEVICES
MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has successfully completed Phase I animal feasibility studies in sheep of two models of a novel implantable arterial filtration technology device designed to prevent strokes by diverting embolic particles flowing through the bloodstream. These two models of MIVT's unique Aortic Embolic Protection Device (AEPD) are being designed to prevent both major types of embolic strokes -- those triggered by heart surgery and catheterization, and those that occur naturally, not in connection with such procedures.Full Report - HTML

MIVT: MIV THERAPEUTICS SUCCESSFULLY COMPLETES ANIMAL FEASIBILITY STUDIES OF STROKE-PREVENTION DEVICES
MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has successfully completed Phase I animal feasibility studies in sheep of two models of a novel implantable arterial filtration technology device designed to prevent strokes by diverting embolic particles flowing through the bloodstream. These two models of MIVT's unique Aortic Embolic Protection Device (AEPD) are being designed to prevent both major types of embolic strokes -- those triggered by heart surgery and catheterization, and those that occur naturally, not in connection with such procedures.Full Report - HTML

MIVT: MIV THERAPEUTICS GAINS 15% ON 4X AVERAGE VOLUME AND STOCK HITS 5-WEEK HIGH
July 11, 2005 (FinancialWire) MIV Therapeutics gained 15.38% Friday on volume trading at 1,311,234, over 4.6 times the average volume of 285,017 to close at $0.75. MIV Therapeutics stock has also reached a 5-week high and gained more than 40% since the company's last update, which came on June 28. Full Report - HTML

MIVT: MIV THERAPEUTICS HITS FINACIAL TARGETS AND GOALS FOR FIRST SIX MONTHS OF 2005
July 8, 2005 (FinancialWire) MIV Therapeutics, Inc. (OTCBB: MIVT) has hit scientific and business achievements in a corporate update. The company' noted their achievements which include execution of a Letter of Intent to acquire the world's third largest manufacturer of drug-eluting stents Full Report - HTML

MIVT: MIV THERAPEUTICS GAINED 17% ON 4X AVERAGE VOLUME
July 6, 2005 (FinancialWire) MIV Therapeutics Inc. (OTCBB: MIVT) gained 17.31% Tuesday on volume trading of 1,185,184, which is 4.4 times the average volume of 266,988 to close at $0.61. Full Report - HTML

MIVT: MIV THERAPEUTICS SPECULATIVE GAINS 11.77% INTRADAY ON 2X AVERAGE VOLUME AFTER RESEARCH NOTE
June 30, 2005 (FinancialWire) (Investrend Research Syndicate) MIV Therapeutics (OTCBB: MIVT) gained 11.77% intraday to $0.57 before closing at $0.51 on volume of 435,318, almost twice the average volume of 279,442 after Ernest C. Schlotter, a senior analyst with InvesTrend affiliate SISM Research reiterated his Speculative Buy/4 rating for MIV Therapeutics (OTCBB: MIVT) with a 12-month price target of $1.50 . Full Report - HTML

MIVT: MIV THERAPEUTICS SPECULATIVE BUY/4 RATING $1.50 REITERATED BY INVESTREND RESEARCH AFFILATE SISM RESEARCH
June 29, 2005 (FinancialWire) (Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst with InvesTrend affiliate SISM Research, and a four-star analyst according to San Francisco-based StarMine, has reiterated his Speculative Buy/4 rating for MIV Therapeutics (OTCBB: MIVT) with a 12-month price target of $1.50 after the company announced that its HAp-coated cardiovascular stents demonstrate excellent safety and feasibility at 3-month follow-up after porcine implantation. Full Report - HTML

MIVT: MIV THERAPEUTICS ANNOUNCES AVAILABILITY OF RESEARCH REPORT PROJECTING 300% SHARE VALUE INCREASE IN 12 MONTHS
VANCOUVER, British Columbia--(BUSINESS WIRE)--June 28, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced the availability of an extensive research and investment report by SISM Research & Investment Services that projects a 300% increase in share appreciation, and reaffirms a Speculative Buy/4 recommendation of the Company's stock with a 12-month target price of $1.50. Full Report - HTML
Summary in PDF

MIVT: MIV THERAPEUTICS REPORTS ON SUCCESSFUL PROGRESS OF ANIMAL STUDIES OF HYDROXYAPATITE IN PREPARATION FOR CLINICAL TRIALS
VANCOUVER, British Columbia--(BUSINESS WIRE)--June 23, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced that its proprietary Hydroxyapatite (HAp) stent coating has demonstrated excellent performance and biocompatibility in key areas assessed at the three-month follow-up stage of an ongoing study in which HAp-coated stents were implanted in pig cardiovascular arteries. The results of the study, conducted at The Methodist Hospital Research Institute in cooperation with Texas Heart Institute, pave the way for upcoming human clinical trials of HAp coatings for stents. Full Report - HTML

MIVT: MIV THERAPEUTICS EXERCISES OPTION TO LICENSE ADDITIONAL PROPRIETARY TECHNOLIGES FOR BIOCOMPATIBLE DRUG-ELUTING COATINGS
VANCOUVER, British Columbia--(BUSINESS WIRE)--June 8, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced it has exercised the option provided in its Collaborative Research Agreement with the University of British Columbia (UBC) to license two additional technologies for advanced biocompatible and drug-eluting coatings for cardiovascular stents and other medical devices. Full Report - HTML

MIVT: MIV THERAPEUTICS FEATURED IN RESPECTED EUROPE-BASED MEDICAL INDUSTY PUBLICATION CARDOPVASCULAR NEWS
VANCOUVER, British Columbia--(BUSINESS WIRE)--June 6, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced that the Company has been featured in a recent edition of respected European medical industry publication, Cardiovascular News. The article discussed the Company's recently announced agreement to acquire Sahajanand Medical Technologies (SMT), a manufacturer of advanced drug-eluting coronary stents based in Surat, India. Full Report - HTML

MIVT: MIV THERAPEUTICS NAMES DHIRAJLAL KOTADIA, CEO OF SAHAJANAND, AS CO-CHAIRMAN AND MANAGING DIRECTOR OF INTERNATIONAL OPERATIONS
British Columbia--(BUSINESS WIRE)--May 24, 2005-- MIV Therapeutics Inc., (OTCBB: MIVT - News) a developer of next-generation biocompatible coatings and drug delivery technologies, announced today that it has appointed successful business and biomedical technology innovator Dhirajlal Kotadia, founder and CEO of India-based advanced stent manufacturer Sahajanand Medical Technologies, to the position of Co-Chairman and Managing Director of International Operations for MIVT. Full Report - HTML

MIVT: SMALLCAP SENTINEL: STENT COMPANY LOOKS TO ENHANCE “FLOW“ OF BIOCOMPATIBLE DEVICE TECHNOLOGY
IRVINE, Calif., May 20, 2005 (PRIMEZONE) -- An informational report on a biotech company developing technology to increase the safety and effectiveness of drug-coated cardiovascular stents has been made available free of charge to readers of SmallCap Sentinel. This news comes on the heels of a new announcement by MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) detailing the expansion of the company's intellectual property portfolio of next-generation biocompatible medical device coatings. Full Report - HTML

MIVT: MIV THERAPEUTICS EXPANDS INTELLECTUAL PROPERTY PORTFOLIO WITH NEW TECHNOLIGES FOR NEXT-GENERATION BIOCOMPATIBLE MEDICAL DEVICE COATINGS
Proprietary Technologies, Licensed from Univ. of British Columbia, Include New Coatings for Advanced Drug-Eluting Applications. Full Report - HTML

MIVT: MIV THERAPEUTICS COMMENCES ANIMAL TRIALS OF STROKE-PREVENTING PROPRIETARY DEVICE DEVELOPED BY RECENTLY-ACQUIRED SAGAX
IRVINE, MIV Therapeutics Commences Animal Trials of Stroke-Preventing Proprietary Device Developed by Recently-Acquired SagaX. Revolutionary Filter Designed to Significantly Reduce Risk of Cardioembolic Stroke Caused by Cardiac Procedures. Full Report - HTML

MIVT: MIV THERAPEUTICS MEDICAL OFFICER DR. DOV SHIMON INTERVIEWED BY BIOMEDDISCOVERIES.COM ABOUT NEW CLINICAL EVIDENCE OF STENT RISKS
MIV Therapeutics Medical Officer Dr. Dov Shimon Interviewed by BiomedDiscoveries.com about New Clinical Evidence of Stent Risks Study in Journal of the American Medical Association Finds Higher Rate of Complications and Death with Industry-Leading Drug-Coated Stents. Full Report - HTML

MIVT: MIV THERAPEUTICS INC. RATED “OUTPERFORM“, TARGET $1.53 BY INVESTREND AFFILIATE BEACON EQUITY RESEARCH
NEW YORK--(BUSINESS WIRE)--April 26, 2005--(Investrend Research Syndicate) MIV Technologies, Inc. (OTCBB: MIVT - News) has been rated "Outperform," with a price target of $1.53 by Investrend Research affiliate Beacon Equity Research. The report is authored by Senior Research Analyst, Shailesh Dhuri.Full Report - HTML

MIVT: FOURTEEN UNDER-RECOGNIZED COMPANIES PRESENT NEW OPPORTUNITIES THIS SATURDAY AT THE SCIA NATIONAL SMALL CAP SOUTHERN CALIFORNIA INVESTMENT CONFRENCE IN ORGANGE COUNTY.
MONARCH BEACH, CA--(MARKET WIRE)--Mar 30, 2005 -- Southern California Investment Association, Inc. -- SCIA -- important small cap conference from 7:15 a.m. - 1 p.m. to this Saturday, April 2nd, at the Orange County Airport Hilton (800-Hiltons), 18800 MacArthur Boulevard, Irvine, CA 92612, conveniently located across from the John Wayne Airport (SNA). Registration required. Full Report - HTML

MIVT: MIV THERAPEUTICS REICEIVES GOVERNMENT GRANT TO EXPEDITE DEVELOPMENT OF PROPRIETARY HAP STENT COATING FOR DRUG DELIVERY TECHNOLOGIES
VANCOUVER, B.C.--(BUSINESS WIRE)--March 22, 2005--MIV Therapeutics Inc. (MIVT: OTCBB) announced today that its wholly-owned subsidiary, MIVI Technologies Inc., that is involved in the research and development of multilayer coating technologies with drug eluting capability for cardiovascular stents and other implantable devices, has received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents". The National Research Council approved MIVI's application following an in depth familiarization with the advanced concept of novel technologies proposed by MIVI, and a review of the Company's organizational and fiscal capability to carry on with the proposed USD 1 million+ R&D program. Full Report - HTML

MIVT: MIV THERAPEUTICS COMPLETES ACQUISTIONN OF SAGAX, DEVELOPER OF ADVANCED STROKE PREVENTION TECHNOLOGY
VANCOUVER, B.C.--(BUSINESS WIRE)--March 18, 2005-- MIV Therapeutics, Inc. (OTCBB: MIVT - News) a developer of next-generation biocompatible coatings and drug delivery technologies, announced today that it has executed an agreement to acquire SagaX Medical Technologies, Inc., a company developing a range of proprietary solutions that decrease likelihood of strokes and other frequently-occurring, serious complications that can result from cardiac procedures, as well as naturally occurring Cardioembolic Strokes. Full Report - HTML

MIVT: MIV THERAPEUTICS CEO DISCUSSES COMPANY’S ADVANCED STENT TECHNOLOGY IN ONLINE INTERVIEW WITH SAMLLCAPINSIGHTS.COM
LOS ANGELES--(BUSINESS WIRE)--March 17, 2005--SmallcapInsights.com, http://www.SmallcapInsights.com, the online source for exclusive commentary, research, interviews and other key investor information, has announced the availability of an audio interview with Alan Lindsay, CEO of MIV Therapeutics, a developer of next-generation biocompatible coatings and drug delivery technologies. Full Report - HTML

MIVT:MIV THERAPEUTICS GAINS 26.32% ON 10X AVERAGE VOLUME
March 16, 2005 (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 26.32% Tuesday on volume of 2,461,227, ten times its average volume of 243,681, to close at $0.60. MIV Therapeutics is covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated coverage with a "Buy" rating and a $1.50 target, which was reiterated June 18. 2004 SISM Research is distributed by the Investrend Research Syndicate. Full Report - HTML

MIVT: MIV THERAPEUTICS GAINES 39.71% ON 15X AVERAGE VOLUME, WILL PARTICIPATE IN WEBCAST
March 15, 2005 (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 39.71% Monday on volume of 3,147,693, some 15 times its average volume of 200,818, to close at $0.475. At the same time, it was announced that the company, along with Xenomics (OTCBB: XNOM) and Biophan Technologies (OTCBB: BIPH), will present at a webcast March 23, beginning at noon. The webcast is sponsored by Trilogy Capital Partners. The conference moderator is A.J. Cervantes, president of Trilogy, and the keynote speaker will be Dr. John Faessel. Registration for the event is at http://www.trilogy-capital.com
MIV Therapeutics is covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated coverage with a "Buy" rating and a $1.50 target, which was reiterated June 18.. SISM Research is distributed by the Investrend Research Syndicate.
. Full Report - HTML

MIVT: MIV THERAPEUTICS ANNOUNCES 2004 YEAR-END REVIEW: MILESTONES ACHIEVED IN DEVELOPMENT OF REVOLUTINARY COATINGS FOR MEDICAL DEVICES
VANCOUVER, British Columbia--(BUSINESS WIRE)--March 15, 2005--MIV Therapeutics Inc., a developer of next-generation drug-eluting coatings that inhibit the rejection of implanted medical devices, has announced the Company's successful achievement of all key milestones planned in its 2004 research and development program. The Company is progressing toward commercialization of a revolutionary new surface coating technology that has the potential to vastly improve the human body's acceptance of implanted medical devices, as well as enhance the functionality of those devices. The announcement was made by Alan Lindsay, President and CEO of MIVT. Technology Increases Body's Acceptance of Implanted Devices, Provides Advanced Therapeutic Functionality. Full Report - HTML

MIVT: MIV THERAPETEUTICS AND SAHAJANAND MEDICAL TECHNOLOGIES TO JOIN FORCES TO FORM WORLD CLASS DRUG-ELUTING CORONARY STENT COMPANY
VANCOUVER, B.C.--(BUSINESS WIRE)--March 11, 2005--MIV Therapeutics Inc., a developer of next-generation biocompatible coatings and drug delivery technologies, announced today that it has executed a letter of intent to acquire Sahajanand Medical Technologies, one of the world's largest manufacturers of advanced coronary stents. Alan Lindsay, Chairman, President and CEO of MIVT, made the announcement. Transaction will Bring Company $20 Million Approximate Annual Revenues and International Production and Distribution. Full Report - HTML